When was EVerZom founded?

EVerZom was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is EVerZom located?

EVerZom is headquartered in Paris, France.

Who is the current CEO of EVerZom?

Jeanne Volatron of EVerZom. They have also founded 1 company.

How many employees does EVerZom have?

As of Sep 30, 2026, the latest employee count at EVerZom is 26.

Is EVerZom a funded company?

EVerZom is a funded company, having raised a total of $1.32M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 02, 2020.

When was the latest funding round of EVerZom?

EVerZom's latest funding was a $***** Grant (prize money) round on Jun 17, 2025, with participation from 1 investor.

Where does EVerZom rank among its competitors?

EVerZom ranks 28th amongst 2025 active competitors, of which 448 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of EVerZom?

EVerZom's top competitors include Antheia, Transcenta and Akeso. Among them, One Biosciences secured the most recent funding round in September, 2026.

EVerZom - 2026 Company Profile, Team, Funding & Competitors

Company Details

EVerZom develops a technology platform for the production of extracellular vesicles. The extracellular vesicles are generated by Mesenchymal stem cells having regenerative properties. This method can be used to apply turbulence stimulation to cells.

Website: everzom.com
Email ID: *****@everzom.com
Phone Number: +33 **********

Key Metrics

Founded Year

2018

Location

Paris, France

Stage

Seed

Total Funding

$1.32M in 5 rounds

Latest Funding Round

Grant (prize money), Jun 17, 2025, $*****

Investors

EIC Fund & 4 more

Ranked

28^th among 2025 active competitors

Employee Count

26 as on Sep 30, 2026

Similar Companies

Antheia & 2731 more

View EVerZom's full profile

EVerZom has raised a total funding of $1.32M over 5 rounds. Its first funding round was on Dec 02, 2020. Its latest funding round was a Grant (prize money) round on Jun 17, 2025 for $*****. 1 investor participated in its latest round. EVerZom has 5 institutional investors.

Here is the list of recent funding rounds of EVerZom:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2025	1735062	Grant (prize money)	6662767	4471619	5881423	2566953
Jun 01, 2022	2227479	Grant (prize money)	2477068	1485921	7396747	Europa
May 01, 2022	7143675	Grant (prize money)	8264908	5377079	5989079	Europa

Access funding benchmarks and valuations. Sign up today!

View details of EVerZom's funding rounds and investors

The founders of EVerZom are Amanda Silva Brun, Max Piffoux, Nicolas Rousseau and Jeanne Volatron. Jeanne Volatron is the CEO of EVerZom.

Here are the details of EVerZom's key team members:

Amanda Silva Brun: Co-founder of EVerZom and founder of 1 other company.
Max Piffoux: Co-Founder & CTO of EVerZom.
Nicolas Rousseau: Co-Founder - COO of EVerZom.
Jeanne Volatron: Co-Founder & CEO of EVerZom.
Contact Info: 1 email address

View details of EVerZom's Founder profiles and Board Members

EVerZom's employee count trend

EVerZom has 26 employees as of Sep 26. Here is EVerZom's employee count trend over the years:

Uncover EVerZom's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EVerZom include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of EVerZom, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	64/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
9th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
28th	EVerZom 2018, Paris (France), Seed	Developer of a technology platform for the production of extracellular vesicles	$1.32M	EIC Fund, Bpifrance & 3 others	60/100